FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988430662> ?p ?o ?g. }

• W1988430662 endingPage "578" @default.
• W1988430662 startingPage "571" @default.
• W1988430662 abstract "Severe combined immunodeficient (SCID) mice injected i.v. with the human T-ALL cell line CCRF CEM (SCID-CEM mice) develop within 50 days life-threatening multi-organ growth of leukaemia cells. The development of leukaemia in SCID-CEM mice treated with three 10 microg i.v. doses of the anti-CD7 immunotoxin (IT) HB2-SAPORIN or the anti-CD38 IT OKT10-SAPORIN was significantly delayed compared with PBS sham-treated animals but 90% of animals treated with either IT eventually developed disseminated leukaemia cell growth. In contrast treatment of SCID-CEM mice with a combination of both ITs led not only to a significantly greater delay in time to leukaemia development but also in the numbers of animals remaining leukaemia free (60%). The native HB2 and OKT10 antibodies (both murine IgG1antibodies) exerted significant, though relatively weak therapeutic effects, probably mediated through an antibody-dependent cellular cytotoxicity (ADCC) mechanism. Moreover, there was no in vivo additivity of therapeutic effect when both antibodies were used in combination. Apparent, however, was that the combination of HB2-SAPORIN IT with OKT10 antibody led to an intermediate therapeutic effect that was significantly greater than that obtained when either was used alone but significantly less than that obtained when the two IT combination was utilized. This was similarly the case for the combination of OKT10-SAPORIN IT with HB2 antibody though the effect was less pronounced in this instance. This result suggests that the therapeutic effect of IT + antibody treatment results from an additivity between antibody-mediated delivery of saporin combined with a SCID mouse NK cell-mediated ADCC attack on the target cell directed through target cell bound antibody Fc engagement with FcgammaRIII on the NK cell surface. The combination of both ITs however gave the best therapeutic outcome in SCID-CEM mice probably as the result of (i) delivery of greater amounts of saporin to target CEM cells positive for both CD7 and CD38, (ii) delivery of an effective dose of saporin to CEM cells downregulated or negative for one of the target antigens and (iii) through ADCC mechanisms that interact additively with IT action. We have previously proposed that combination IT therapy would be one means of overcoming the problem of heterogeneity of antigen expression within a global tumour cell population and these additional findings support this and provide a further strengthening of the rationale for employing cocktails of ITs for the treatment of human malignancies." @default.
• W1988430662 created "2016-06-24" @default.
• W1988430662 creator A5007899376 @default.
• W1988430662 creator A5040607214 @default.
• W1988430662 creator A5044112726 @default.
• W1988430662 creator A5052113919 @default.
• W1988430662 creator A5058894116 @default.
• W1988430662 date "2001-01-01" @default.
• W1988430662 modified "2023-10-10" @default.
• W1988430662 title "Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin" @default.
• W1988430662 cites W145820509 @default.
• W1988430662 cites W1487869417 @default.
• W1988430662 cites W1616371879 @default.
• W1988430662 cites W1929422909 @default.
• W1988430662 cites W1989877475 @default.
• W1988430662 cites W2006140229 @default.
• W1988430662 cites W2006416369 @default.
• W1988430662 cites W2018289835 @default.
• W1988430662 cites W2031988182 @default.
• W1988430662 cites W2042335553 @default.
• W1988430662 cites W2044094798 @default.
• W1988430662 cites W2055707343 @default.
• W1988430662 cites W2094410931 @default.
• W1988430662 cites W2098045599 @default.
• W1988430662 cites W2100837269 @default.
• W1988430662 cites W2132821697 @default.
• W1988430662 cites W220717814 @default.
• W1988430662 cites W2351157948 @default.
• W1988430662 cites W4238917219 @default.
• W1988430662 cites W4298217633 @default.
• W1988430662 cites W58638097 @default.
• W1988430662 doi "https://doi.org/10.1054/bjoc.2000.1633" @default.
• W1988430662 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2363766" @default.
• W1988430662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11207056" @default.
• W1988430662 hasPublicationYear "2001" @default.
• W1988430662 type Work @default.
• W1988430662 sameAs 1988430662 @default.
• W1988430662 citedByCount "35" @default.
• W1988430662 countsByYear W19884306622012 @default.
• W1988430662 countsByYear W19884306622013 @default.
• W1988430662 countsByYear W19884306622014 @default.
• W1988430662 countsByYear W19884306622015 @default.
• W1988430662 countsByYear W19884306622018 @default.
• W1988430662 countsByYear W19884306622020 @default.
• W1988430662 countsByYear W19884306622022 @default.
• W1988430662 crossrefType "journal-article" @default.
• W1988430662 hasAuthorship W1988430662A5007899376 @default.
• W1988430662 hasAuthorship W1988430662A5040607214 @default.
• W1988430662 hasAuthorship W1988430662A5044112726 @default.
• W1988430662 hasAuthorship W1988430662A5052113919 @default.
• W1988430662 hasAuthorship W1988430662A5058894116 @default.
• W1988430662 hasBestOaLocation W19884306621 @default.
• W1988430662 hasConcept C115085202 @default.
• W1988430662 hasConcept C159654299 @default.
• W1988430662 hasConcept C203014093 @default.
• W1988430662 hasConcept C2781260279 @default.
• W1988430662 hasConcept C40677261 @default.
• W1988430662 hasConcept C502942594 @default.
• W1988430662 hasConcept C542903549 @default.
• W1988430662 hasConcept C71924100 @default.
• W1988430662 hasConceptScore W1988430662C115085202 @default.
• W1988430662 hasConceptScore W1988430662C159654299 @default.
• W1988430662 hasConceptScore W1988430662C203014093 @default.
• W1988430662 hasConceptScore W1988430662C2781260279 @default.
• W1988430662 hasConceptScore W1988430662C40677261 @default.
• W1988430662 hasConceptScore W1988430662C502942594 @default.
• W1988430662 hasConceptScore W1988430662C542903549 @default.
• W1988430662 hasConceptScore W1988430662C71924100 @default.
• W1988430662 hasIssue "4" @default.
• W1988430662 hasLocation W19884306621 @default.
• W1988430662 hasLocation W19884306622 @default.
• W1988430662 hasLocation W19884306623 @default.
• W1988430662 hasLocation W19884306624 @default.
• W1988430662 hasOpenAccess W1988430662 @default.
• W1988430662 hasPrimaryLocation W19884306621 @default.
• W1988430662 hasRelatedWork W1482358613 @default.
• W1988430662 hasRelatedWork W1985837387 @default.
• W1988430662 hasRelatedWork W2034819664 @default.
• W1988430662 hasRelatedWork W2049463037 @default.
• W1988430662 hasRelatedWork W2098045599 @default.
• W1988430662 hasRelatedWork W2115013237 @default.
• W1988430662 hasRelatedWork W2418109979 @default.
• W1988430662 hasRelatedWork W2573328667 @default.
• W1988430662 hasRelatedWork W3193741685 @default.
• W1988430662 hasRelatedWork W4290297832 @default.
• W1988430662 hasVolume "84" @default.
• W1988430662 isParatext "false" @default.
• W1988430662 isRetracted "false" @default.
• W1988430662 magId "1988430662" @default.
• W1988430662 workType "article" @default.